(Q40207847)

18 September 2017

title

Development of echinocandin-resistant Candida albicans candidemia following brief prophylactic exposure to micafungin therapy (English)

1 reference

18 September 2017

1 reference

1 reference

M A Ruggero

1

1 reference

18 September 2017

J E Topal

series ordinal

2

1 reference

18 September 2017

publication date

9 May 2014

1 reference

Transplant Infectious Disease

18 September 2017

published in

1 reference

18 September 2017

volume

16

1 reference

18 September 2017

issue

3

1 reference

18 September 2017

page(s)

469-472

1 reference

Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia

18 September 2017

cites work

1 reference

Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america

21 January 2018

1 reference

European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update

21 January 2018

1 reference

Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation

21 January 2018

1 reference

Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains

21 January 2018

1 reference

A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility

21 January 2018

1 reference

Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints

21 January 2018

1 reference

Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.

21 January 2018

1 reference

Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates

21 January 2018

1 reference

Fungal ß(1,3)-D-glucan synthesis

21 January 2018

1 reference

Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment

21 January 2018

1 reference

Resistance to echinocandin-class antifungal drugs

21 January 2018

1 reference

Rapid emergence of echinocandin resistance in Candida glabrata resulting in clinical and microbiologic failure.

21 January 2018

1 reference

Breakthrough invasive candidiasis in patients on micafungin

21 January 2018

1 reference

Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin:review of the literature

21 January 2018

1 reference

Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geogr

21 January 2018

1 reference

Disseminated Candidiasis caused by Candida albicans with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin

21 January 2018

1 reference

Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance.

21 January 2018

1 reference

Resistance to echinocandins comes at a cost: the impact of FKS1 hotspot mutations on Candida albicans fitness and virulence

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/TID.12230

1 reference

18 September 2017

1 reference